Q4 2017 EPS Estimates for Icon Plc (ICLR) Lowered by Analyst
Icon Plc (NASDAQ:ICLR) – Investment analysts at KeyCorp cut their Q4 2017 earnings per share estimates for shares of Icon in a research note issued on Tuesday. KeyCorp analyst D. Hooker now anticipates that the medical research company will post earnings of $1.39 per share for the quarter, down from their prior estimate of $1.41. KeyCorp currently has a “Buy” rating and a $130.00 target price on the stock.
Other equities analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Icon from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. ValuEngine cut shares of Icon from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. Jefferies Group lifted their price target on shares of Icon from $122.00 to $132.00 and gave the stock a “buy” rating in a research note on Monday, October 9th. Robert W. Baird reaffirmed a “buy” rating and set a $123.00 price target on shares of Icon in a research note on Thursday, October 12th. Finally, Barclays lifted their price target on shares of Icon from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Friday, October 27th. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $121.82.
Icon (NASDAQ:ICLR) last released its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.32 by $0.03. Icon had a net margin of 16.37% and a return on equity of 28.42%. The firm had revenue of $440.30 million during the quarter, compared to analysts’ expectations of $438.09 million. During the same period in the previous year, the company earned $1.19 EPS. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. GRATRY & Co LLC lifted its holdings in Icon by 5.1% during the 3rd quarter. GRATRY & Co LLC now owns 30,144 shares of the medical research company’s stock valued at $3,433,000 after buying an additional 1,474 shares in the last quarter. GSA Capital Partners LLP lifted its holdings in Icon by 116.3% during the 2nd quarter. GSA Capital Partners LLP now owns 9,337 shares of the medical research company’s stock valued at $913,000 after buying an additional 5,020 shares in the last quarter. BT Investment Management Ltd bought a new stake in Icon during the 3rd quarter valued at about $325,000. Insight Capital Research & Management Inc. bought a new stake in Icon during the 3rd quarter valued at about $1,359,000. Finally, NorthCoast Asset Management LLC lifted its holdings in Icon by 23.4% during the 3rd quarter. NorthCoast Asset Management LLC now owns 18,016 shares of the medical research company’s stock valued at $2,052,000 after buying an additional 3,419 shares in the last quarter. Institutional investors own 89.66% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Q4 2017 EPS Estimates for Icon Plc (ICLR) Lowered by Analyst” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/12/q4-2017-eps-estimates-for-icon-plc-iclr-lowered-by-analyst.html.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.